All In Biotech

Drug Trial Radar · NCT00066573

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer

Last checked: Nov 19, 2026Latest source record: Aug 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 7,576 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,576

Actual

Start

Jun 6, 2003

Primary completion

Nov 7, 2010

Study completion Jan 6, 2012

Sponsor

Lead sponsor
NCIC Clinical Trials GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; SWOG Cancer Research Network; ETOP IBCSG Partners Foundation
First posted
Aug 7, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy, using exemestane or anastrozole, may fight breast cancer by reducing the production of estrogen. It is not yet known whether exemestane is more effective than anastrozole in preventing the recurrence of breast cancer. PURPOSE: This randomized phase III trial is studying exemestane to see how well it works compared to anastrozole in preventing cancer recurrence in postmenopausal women who have undergone surgery for primary breast cancer.

Conditions

  • Breast Cancer

Interventions

  • anastrozoleDrug

    Given orally

  • exemestaneDrug

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free SurvivalTime frame: 5 years

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Lethbridge Cancer Centre

    Lethbridge, Alberta, Canada

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • Penticton Regional Hospital

    Penticton, British Columbia, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • BCCA - Vancouver Island Cancer Centre

    Victoria, British Columbia, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada

  • The Moncton Hospital

    Moncton, New Brunswick, Canada

  • The Vitalite Health Network - Dr. Leon Richard

    Moncton, New Brunswick, Canada

  • Atlantic Health Sciences Corporation

    Saint John, New Brunswick, Canada

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, Canada

  • Quinte Healthcare Corporation

    Belleville, Ontario, Canada

  • Cambridge Memorial Hospital

    Cambridge, Ontario, Canada

  • Regional Cancer Program of the Hopital Regional

    Greater Sudbury, Ontario, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, Canada

  • Cancer Centre of Southeastern Ontario at Kingston

    Kingston, Ontario, Canada

  • Grand River Regional Cancer Centre

    Kitchener, Ontario, Canada

  • London Regional Cancer Program

    London, Ontario, Canada

  • Credit Valley Hospital

    Mississauga, Ontario, Canada

  • Stronach Regional Health Centre at Southlake

    Newmarket, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • Algoma District Cancer Program

    Sault Ste. Marie, Ontario, Canada

  • Niagara Health System

    St. Catharines, Ontario, Canada

  • Thunder Bay Regional Health Science Centre

    Thunder Bay, Ontario, Canada

  • Odette Cancer Centre

    Toronto, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Mount Sinai Hospital

    Toronto, Ontario, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Trillium Health Centre - West Toronto

    Toronto, Ontario, Canada

  • Windsor Regional Cancer Centre

    Windsor, Ontario, Canada

  • PEI Cancer Treatment Centre,Queen Elizabeth Hospital

    Charlottetown, Prince Edward Island, Canada

  • Centre de Sante et de services sociaux de Gatineau

    Gatineau, Quebec, Canada

  • Hopital Charles LeMoyne

    Greenfield Park, Quebec, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, Canada

  • CHA-Hopital Du St-Sacrement

    Québec, Quebec, Canada

  • Centre hospitalier universitaire de Sherbrooke

    Sherbrooke, Quebec, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.